Scintilla Pharmaceuticals has entered a binding term sheet to acquire Semnur Pharmaceuticals for a purchase consideration of up to $200m.

According to the agreement, Scintilla Therapeutics will pay an initial payment to Semnur of $40m in cash and $20m in shares of common stock, while the remaining $140m will be paid upon achievement of development, product approval and commercial milestones.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The acquisition enables Scintilla Pharma to broaden its pain management pipeline.

Lonza Group Ltd plans to strengthen its nutritional ingredients portfolio and expand its business in areas such as cognitive and diabetic health by acquiring InterHealth Nutraceuticals Inc.

"The acquisition enables Scintilla Pharma to broaden its pain management pipeline."

The company expects the transaction to cost approximately $300m and be completed in September 2016.

The US-based, wholly-owned subsidiary of Piramal Enterprises Limited (PEL), a pharmaceutical company based in Mumbai, India, has agreed to acquire Ash Stevens Inc.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The target company is a US-based, contract development and manufacturing organisation. The purchase consideration for the acquisition is fixed at $42.95m to be paid in cash, in addition to up to $10m in earn-out consideration.

PEL expects to strengthen its manufacturing capabilities through the acquisition, which is expected to be completed by the end of this month.